聯(lián)系電話
深圳艾利蒙生物科技有限公司
中級會員·6年
- 聯(lián)系人：
- 任經(jīng)理
- 電話：
- 微信：18237190368；QQ：1223408098
- 手機：
- 18237190368
- 地址：
- 深圳市龍崗區(qū)龍平西路
- 個性化：
- www.szelebio.com
掃一掃訪問手機商鋪
利格列汀雜質(zhì) 全套對照品
深圳艾利蒙生物科技有限公司可提供利格列汀雜質(zhì)全套，并隨貨提供COA證書，HPLC，NMR，MS圖譜，10mg/25mg/50mg/100mg等多種規(guī)格可選。
部分雜質(zhì)長期備有現(xiàn)貨，可快速發(fā)貨，并可根據(jù)客戶需要提供雜質(zhì)定制服務。
利格列汀的相關(guān)介紹：
中文名稱：利格列汀
中文別名：8-[(3R)-3-氨基-1-哌啶基]-7-(2-丁炔基)-3,7-二氫-3-甲基-1-[(4-甲基-2-喹唑啉基)甲基]-1H-嘌呤-2,6-二酮；利拉利汀;
英文名稱：linagliptin
英文別名：Trajenta；BI-1356-BS；Ondero；BI-1356；Linagliptin；Tradjenta；8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione;
CAS號：668270-12-0
分子式：C25H28N8O2
分子量：472.23400
結(jié)構(gòu)式：
適應癥：
利格列汀與二甲雙胍和磺脲類藥物聯(lián)合使用，配合飲食控制和運動，可用于成年2型糖尿病患者的血糖控制。
利格列汀雜質(zhì) 全套對照品
利格列汀雜質(zhì)為我司優(yōu)勢雜質(zhì)，長期備有庫存，發(fā)貨快。雜質(zhì)結(jié)構(gòu)式及更多其他雜質(zhì)對照品，可進入我公司展臺詳細查看。
附：利格列汀雜質(zhì)列表：
中文名稱 | 英文名稱 |
利格列汀標準品 | Linagliptin |
利格列汀雜質(zhì)1 | 7-(but-2-yn-1-yl)-8-((2-hydroxyethyl)amino)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione |
利格列汀雜質(zhì)2 | 2-((R)-3-aminopiperidine-1-carbonyl)-N-((R)-1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)benzamide |
利格列汀雜質(zhì)3 | N-Phthalimide-linagliptin |
利格列汀雜質(zhì)4 | Linagliptin Impurity S |
利格列汀雜質(zhì)5 | N1,N2-bis((R)-1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)phthalamide |
利格列汀雜質(zhì)6 | (R)-2-((1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamoyl)benzoic acid |
利格列汀雜質(zhì)7 | Linagliptin Diene Impurity |
利格列汀雜質(zhì)8 | Linagliptin Acetamide |
利格列汀雜質(zhì)9 | 8-bromo-1,7-di(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione |
利格列汀雜質(zhì)10 | (R)-tert-butyl (1-(1,7-di(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate |
利格列汀雜質(zhì)11 | (R)-8-(3-aminopiperidin-1-yl)-1,7-di(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione |
利格列汀雜質(zhì)12 | 8-bromo-3-methyl-7-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione |
利格列汀雜質(zhì)13 | (R)-tert-butyl (1-(3-methyl-7-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate |
利格列汀雜質(zhì)14 | (R)-8-(3-aminopiperidin-1-yl)-3-methyl-7-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione |
利格列汀雜質(zhì)15 | (R)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-8-(piperidin-3-ylamino)-1H-purine-2,6(3H,7H)-dione |
利格列汀雜質(zhì)16 | (R)-N-(1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)-2,2,2-trifluoroacetamide |
利格列汀雜質(zhì)17 | (S)-Linagliptin |
利格列汀雜質(zhì)18 | 7-(but-2-yn-1-yl)-8-(dimethylamino)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione |
利格列汀雜質(zhì)19 | N-(2-acetylphenyl)-2-(8-bromo-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)acetamide |
利格列汀雜質(zhì)20 | (R)-tert-butyl (1-(1-(2-((2-acetylphenyl)amino)-2-oxoethyl)-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate |
利格列汀雜質(zhì)21 | (R)-N-(2-acetylphenyl)-2-(8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)acetamide |
利格列汀雜質(zhì)22 | (R)-tert-butyl (1-(7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate |
利格列汀雜質(zhì)23 | (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione |
利格列汀雜質(zhì)24 | (S)-tert-butyl (1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate |
利格列汀雜質(zhì)25 | (R)-7-(but-2-yn-1-yl)-8-(3-((7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)amino)piperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione |
利格列汀雜質(zhì)26 | (R)-N-(1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)formamide |
利格列汀雜質(zhì)27 | 8-bromo-7-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione |
利格列汀雜質(zhì)28 | (R)-8-(3-aminopiperidin-1-yl)-7-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione |
利格列汀雜質(zhì)29 | (R)-1-((4-methylquinazolin-2-yl)methyl)piperidin-3-amine |
深圳艾利蒙生物科技有限公司主營醫(yī)藥標準品及雜質(zhì)對照品，所有雜質(zhì)均提供HPLC，NMR，MS圖譜及CoA證： 舒更葡糖鈉雜質(zhì)，骨化三醇雜質(zhì)，阿法骨化醇雜質(zhì)，艾地骨化醇雜質(zhì)，西格列汀雜質(zhì)，利伐沙班雜質(zhì)，依托考昔雜質(zhì)，左氧氟沙星雜質(zhì)，阿加曲班雜質(zhì)，利奈唑胺雜質(zhì)，匹伐他汀雜質(zhì)，利格列汀雜質(zhì)，替格瑞洛雜質(zhì)，阿哌沙班雜質(zhì)，西他沙星雜質(zhì)，伊馬替尼雜質(zhì)，洛索洛芬鈉雜質(zhì)，普瑞巴林雜質(zhì)，環(huán)苯扎林雜質(zhì)，鹽酸帕洛諾司瓊雜質(zhì)等。
